Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy

Inclusion Criteria:

1. Signed informed consent form

2. Age from 18 years and older

3. Diagnosis: Acute cerebrovascular accident of ischemic type (ischemic stroke)developed within 36 hours before enrollment in the study

4. Motor neurologic deficit measurable using the NIHSS Scale (score for item 5 and/or 6at the time of starting the therapy ≥ 1))

5. Conservative stroke treatment tactics (without reperfusion therapythrombolysis/thrombus extraction)

6. According to the routine clinical practice, the patient is scheduled to receive thetreatment as per one of the following regimens:

• Cytoflavin® 20-40 ml/day as a course of not less than 10 days or

• another neuroprotector - course of not less than 10 days (or withoutneuroprotector)

Exclusion Criteria:

1. NIHSS 1a (coma) score 3 at the time of enrollment

2. Initial severe disablement (corresponding to mRS > 2) requiring external assistancein everyday life before development of stroke

3. History of Parkinson's disease, dementia, multiple sclerosis, and other significantdiseases accompanied by neurologic deficit

4. Severe comorbidity with expected lifespan of not more than 6 months

5. Pregnancy and breastfeeding

6. Any other concomitant medical or serious psychic conditions, which make the patientineligible for participation in the study, restrict lawfulness of obtaining theinformed consent, or can influence the patient's ability to participate in the study